These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 2665884
1. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Johansen JS, Hassager C, Pødenphant J, Riis BJ, Hartwell D, Thomsen K, Christiansen C. Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884 [Abstract] [Full Text] [Related]
2. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis]. Gennari C, Agnusdei D, Gonnelli S. Minerva Endocrinol; 1989 Apr; 14(1):69-74. PubMed ID: 2659955 [Abstract] [Full Text] [Related]
3. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis. Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE. Bone; 1989 Apr; 10(1):3-6. PubMed ID: 2736154 [Abstract] [Full Text] [Related]
4. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study. Gennari C, AgnusDei D, Gonnelli S, Nardi P. Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645 [Abstract] [Full Text] [Related]
5. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD. Osteoporos Int; 1997 Sep; 7(1):29-35. PubMed ID: 9102059 [Abstract] [Full Text] [Related]
6. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis. Need AG, Horowitz M, Morris HA, Walker CJ, Nordin BE. Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513 [Abstract] [Full Text] [Related]
7. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659 [Abstract] [Full Text] [Related]
8. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys. Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, Weaver DS. Bone; 1997 Apr; 20(4):355-64. PubMed ID: 9108356 [Abstract] [Full Text] [Related]
9. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C. Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750 [Abstract] [Full Text] [Related]
10. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. Hassager C, Jensen LT, Johansen JS, Riis BJ, Melkko J, Pødenphant J, Risteli L, Christiansen C, Risteli J. Metabolism; 1991 Feb; 40(2):205-8. PubMed ID: 1988778 [Abstract] [Full Text] [Related]
11. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Need AG, Horowitz M, Bridges A, Morris HA, Nordin BE. Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415 [Abstract] [Full Text] [Related]
12. [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium]. Nuti R, Righi GA, Turchetti V, Vattimo A. Minerva Med; 1984 Jan 28; 75(3-4):109-13. PubMed ID: 6366617 [Abstract] [Full Text] [Related]
13. Effects of nandrolone decanoate on bone mass in established osteoporosis. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG. Maturitas; 1993 Nov 28; 17(3):211-9. PubMed ID: 8133796 [Abstract] [Full Text] [Related]
14. Nandrolone decanoate for men with osteoporosis. Hamdy RC, Moore SW, Whalen KE, Landy C. Am J Ther; 1998 Mar 28; 5(2):89-95. PubMed ID: 10099043 [Abstract] [Full Text] [Related]
15. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions. Geusens P, Dequeker J, Verstraeten A, Nijs J, Van Holsbeeck M. Maturitas; 1986 Dec 28; 8(4):281-9. PubMed ID: 3574141 [Abstract] [Full Text] [Related]
16. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Geusens P, Dequeker J. Bone Miner; 1986 Sep 28; 1(4):347-57. PubMed ID: 3333018 [Abstract] [Full Text] [Related]
17. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis. Chhaparwal M, Saraf ML. Indian J Med Sci; 1998 Jun 28; 52(6):236-8. PubMed ID: 9849033 [No Abstract] [Full Text] [Related]
18. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women. Bird HA, Burkinshaw L, Pearson D, Atkinson PJ, Leatham PA, Hill J, Raven A, Wright V. Ann Rheum Dis; 1987 Mar 28; 46(3):237-43. PubMed ID: 3555359 [Abstract] [Full Text] [Related]
19. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate. Need AG, Nordin BE, Chatterton BE. Osteoporos Int; 1993 Mar 28; 3 Suppl 1():218-22. PubMed ID: 8461566 [No Abstract] [Full Text] [Related]
20. Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. Huang RY, Miller LM, Carlson CS, Chance MR. Bone; 2002 Mar 28; 30(3):492-7. PubMed ID: 11882463 [Abstract] [Full Text] [Related] Page: [Next] [New Search]